معرفی
Thomas Wieland is a Professor and Chair of Experimental Pharmacology at the Medical Faculty Mannheim, Heidelberg University. His research focuses on cardiovascular signaling pathways, particularly the roles of nucleoside diphosphate kinases (NDPK) and G protein-mediated signaling in diseases like diabetic retinopathy and hypertension. He investigates endothelial dysfunction, vascular biology, and the molecular mechanisms underlying cardiovascular pathologies.
Key research interests include the regulation of Rho GTPases, endothelial adherens junctions, and the interplay between metabolic pathways and vascular damage. His work utilizes mouse models, zebrafish embryos, and cultured endothelial cells to study disease mechanisms and identify therapeutic targets. Notably, his group has characterized NDPK B's role in caveolae formation, angiogenesis modulation, and diabetic complications.
Recent studies explore how NDPK isoforms influence tumor metastasis, inflammatory responses, and cardiac remodeling. His findings contribute to understanding how histidine phosphorylation and G protein signaling dysregulation drive vascular pathologies. While no specific grants are listed, his publications highlight collaborative projects involving cardiovascular, metabolic, and oncological research.
Labs/Teams: Experimental Pharmacology group at Heidelberg University, collaborating with departments in cardiology, molecular biology, and clinical medicine.
